Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines. [artículo]
Por: Agudo López, Alba [Instituto de Investigación i+12]
| Agulló Ortuño, María Teresa [Oncología Médica]
| Díaz García, C. Vanesa [Instituto de Investigación i+12]
| López Martín, José Antonio [Oncología Médica]
| Pérez, Carlos [Instituto de Investigación i+12]
.
Colaborador(es): Servicio de Oncología Médica
| Instituto de Investigación imas12
.
Tipo de material: 
Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
![]() |
PC3291 (Navegar estantería) | Disponible |
Formato Vancouver:
Pérez C, Díaz-García CV, Agudo-López A, del Solar V, Cabrera S, Agulló-Ortuño MT et al. Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines. Eur J Med Chem. 2014 Apr 9;76:360-8.
PMID: 24589491
Contiene 28 referencias
Platinum-based drugs, mainly cisplatin, are employed for the treatment of solid malignancies. However, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. Here, the antitumor activity of different trans-sulfonamide platinum complexes in a panel of human cell lines is presented. The cytotoxicity profiles and cell cycle analyses of these platinum sulfonamide complexes were different from those of cisplatin. These studies showed that complex 2b with cyclohexyldiamine and dansyl moieties had the best antitumoral activities.
No hay comentarios para este ejemplar.